Evidence map›Paper›PMID 23439602›Full record

ArticleInvestigative ophthalmology & visual science2013

Epithelial membrane protein 2 controls VEGF expression in ARPE-19 cells.

Shawn A Morales, David G Telander, Deanna Leon, Krisztina Forward, Jonathan Braun, Madhuri Wadehra, Lynn K Gordon

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigative ophthalmology & visual science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Sex-dimorphic gene effects on survival outcomes in people with coronary artery disease.American heart journal plus : cardiology research and practice · 2022
    Article
  5. miR-340-5p mediates the therapeutic effect of mesenchymal stem cells on corneal neovascularization.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022
    Article
  6. [Proliferative vitreoretinopathy prophylaxis : Mission (im)possible].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. A Critical Analysis of the AvailableJournal of ophthalmology · 2017
    Review
  11. Review
  12. Mutations in EMP2 cause childhood-onset nephrotic syndrome.American journal of human genetics · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shawn A MoralesDepartment of Ophthalmology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California 90095, USA.
David G Telander
Deanna Leon
Krisztina Forward
Jonathan Braun
Madhuri Wadehra
Lynn K Gordon
University of California, Los Angeles · USUniversity of California, Davis · US

Funding

Vision Research Core at UCLAP30EY000331 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gregory Darin Field, DAVID S WILLIAMS · 1985 to 2026
$16.8M
Novel Therapies to Prevent Blindness Caused by Proliferative VitreoretinopathyR01EY019909 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GORDON, LYNN K · 2010 to 2013
$1.5M
NEI NIH HHS P30 EY000331NEI NIH HHS R01 EY019909
6 · The paper itself

Abstract

purposeVEGF production by RPE cells has been shown to be important in regulating aberrant angiogenesis in the retina, which is responsible for multiple types of ocular pathology. EMP2 is highly expressed in the RPE and has been shown to regulate FAK activation, which is implicated in VEGF expression in other cell lines. The purpose of this study was to determine whether EMP2 regulates VEGF expression in the RPE cell line, ARPE-19.

methodsARPE-19 cells were engineered to overexpress EMP2. EMP2 siRNA was used to decrease EMP2 expression. The small molecule inhibitor PP2 was used to inhibit FAK activation. VEGF levels were measured by Western blot and ELISA. Functional differences in secreted VEGF were assayed using HUVEC migration.

resultsVEGF expression levels correlated with levels of EMP2. An increase of VEGF by 150% was observed in EMP2 overexpressing cells as compared with ARPE-19 cells. Concordantly, EMP2 knockdown resulted in a 57% decrease in VEGF expression. HUVEC migration (P = 0.01) and vessel tube formation (P < 0.01) were significantly increased when exposed to cell culture supernatants from EMP2 overexpressing cells.

conclusionsThis study establishes a novel connection between EMP2 and VEGF and may reflect either a direct effect through the tetraspan web or an indirect change through FAK activation. This connection is functionally significant. In addition to the direct use of anti-VEGF antibodies, modulation of EMP2 with impact on VEGF is potentially a distinct therapeutic target for the treatment of neovascularization associated with retinal diseases that involve pathologic angiogenesis.

Indexed as

Blotting, WesternCells, CulturedEnzyme-Linked Immunosorbent AssayFocal Adhesion Protein-Tyrosine KinasesGene Expression RegulationHumansMembrane GlycoproteinsProtein Kinase InhibitorsRetinal Pigment EpitheliumVascular Endothelial Growth Factor AEMP2 protein, humanFocal Adhesion Protein-Tyrosine KinasesMembrane GlycoproteinsProtein Kinase InhibitorsVascular Endothelial Growth Factor A

Identifiers

PMID23439602
PMCPMC3626528
OpenAlexW2081866003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.